Its use, new data shows, could boost the economic benefit profile of more “common” drugs-and better inform HTA and payer decision-making.
Barbara Arone
Advertisement
Articles by Barbara Arone
Advertisement
Latest Updated Articles
The Argument for External Comparator AdoptionPublished: June 28th 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
2
Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma
3
FDA Announces Agency-Wide Deployment of Agentic AI Tools
4
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
5
